New HIV vaccine trial aims to spark rare antibodies that could fight the virus
NCT ID NCT06006546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an experimental HIV vaccine in 35 people living with HIV. The goal is to see if the vaccine can safely trigger the body to produce VRC01-class antibodies, which are known to neutralize many HIV strains. Participants will temporarily pause their antiretroviral therapy to see if the vaccine helps control the virus.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atlanta- Ponce
Atlanta, Georgia, 30303, United States
-
BIDMC
Boston, Massachusetts, 02215, United States
-
Birmingham
Birmingham, Alabama, 35294-2170, United States
-
Columbia P&S CRS Site#30329
New York, New York, 10032, United States
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Seattle Vaccine and Prevention CRS (Site # 30331)
Seattle, Washington, 98104, United States
-
The Hope Clinic of the Emory Vaccine Center CRS (Site #31440)
Decatur, Georgia, 30030, United States
-
University of Pittsburg
Pittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.